About Ladinin-1
Ladinin-1 (LAD1) is a protein
from Homo sapiens identified by UniProt accession
O00515, 517 residues long.
MolForge cross-references it against 0 known binders and
37 disease associations.
Target properties
| Protein name | Ladinin-1 |
|---|
| UniProt accession | O00515 |
|---|
| Gene | LAD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 517 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (37)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.41
- triglyceride measurement · score 0.29
- lung adenocarcinoma · score 0.10
- neoplasm · score 0.08
- cardiac troponin T measurement · score 0.06
- cancer · score 0.04
- gonorrhea · score 0.04
- left ventricular structural measurement · score 0.02
- electrocardiography · score 0.02
- squamous cell carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O00515-F1 | alphafold | PREDICTED | 52.83 | — |
Amino-acid sequence (517 residues)
MAVSRKDWSA LSSLARQRTL EDEEEQERER RRRHRNLSST TDDEAPRLSQ NGDRQASASE RLPSVEEAEV PKPLPPASKD EDEDIQSILR TRQERRQRRQ VVEAAQAPIQ ERLEAEEGRN SLSPVQATQK PLVSKKELEI PPRRRLSREQ RGPWALEEES LVGREPEERK KGVPEKSPVL EKSSMPKKTA PEKSLVSDKT SISEKVLASE KTSLSEKIAV SEKRNSSEKK SVLEKTSVSE KSLAPGMALG SGRRLVSEKA SIFEKALASE KSPTADAKPA PKRATASEQP LAQEPPASGG SPATTKEQRG RALPGKNLPS LAKQGASDPP TVASRLPPVT LQVKIPSKEE EADMSSPTQR TYSSSLKRSS PRTISFRMKP KKENSETTLT RSASMKLPDN TVKLGEKLER YHTAIRRSES VKSRGLPCTE LFVAPVGVAS KRHLFEKELA GQSRAEPASS RKENLRLSGV VTSRLNLWIS RTQESGDQDP QEAQKASSAT ERTQWGQKSD SSLDAEV
Explore Ladinin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets